Skip to main content

Advertisement

Table 4 Multivariate analysis of MGMT promoter methylation and its association with the overall survival of GBM patients

From: Epigenetic modulation of the drug resistance genes MGMT, ABCB1 and ABCG2 in glioblastoma multiforme

Variable Haz. ratio p-value [95% Conf. Interval]
Sex    
male 1.488 0.238 0.769 2.876
(ref. female) 1.259 0.602 0.530 2.992
1.724 0.393 0.494 6.024
Age     
50- <60 years 1.734 0.299 0.613 4.903
(ref. <50 years) 1.648 0.394 0.523 5.192
1.183 0.916 0.053 26.577
Age     
60- <70 years 2.567 0.057 0.972 6.780
(ref. <50 years) 3.242 0.039 1.061 9.901
1.417 0.757 0.156 12.826
Age     
≥70 years 6.427 0.001 2.194 18.824
(ref. <50 years) 10.700 0.000 2.998 38.191
2.442 0.445 0.247 24.152
Mean methylation 0.988 0.315 0.964 1.012
level (continuous) 0.975 0.121 0.945 1.007
  1.023 0.403 0.970 1.078
  1. Continuous multivariate Cox model regression analysis of MGMT promoter methylation and its association with the overall survival (OS) of the analyzed patients with glioblastoma multiforme, adjusted for potential risk factors including sex and age at diagnosis and stratified on the variable therapy. Normal typed data: the entire glioblastoma cohort; Italic data: Temozolomide treated glioblastoma patients; Bold face data: Glioblastoma patients without temozolomide treatment (Haz. Ratio, Hazard Ratio; Conf. Interval, Confidence Interval).